You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Scanfil Q4 & CMD: Inside sells not worrying
Head of Research Antti Viljakainen summarizes Scanfil’s Q4’23 and recent CMD: raised bar regarding growth going forward, inside sells and polarized growth is not worrying, still upside potential in the stock.
Read the latest research: Scanfil: Light sigh of relief with guidance, published 2024-02-26
Content:
00:00 Intro
00:10 Polarized growth
01:39 Top picks from CMD
04:28 Inside sales
05:36 Recommendation
Read more about Scanfil!
We also recommend the following videos:
Contract Manufacturers
Incap vs Scanfil: to Buy or not to buy
Scanfil Q3'23: No surprises
Aktier i Vælten - Et tilbageblik på bevægelserne i OMXC25 i 2024, og nogle forudsigelser for 2025
5 forudsigelser for aktiemarkedet i 2025
Aktier i Vælten - Novo Nordisk: Vi må vente på re-eksamen efter skuffende data
Introduction to the Helsinki Stock Exchange | Company Night Dec. 16, 2024
Surgical Science Sweden, Audiocast with teleconference, Press Conference, 2024
View all videos